469. The serotonin 5-HT2A agonist psilocybin in the treatment of neuropathic pain
The International Journal of Neuropsychopharmacology September 1, 2026 E Nield, M Lopez-Canul, A Inserra et al.
Abstract Background Pain conditions are major health problems resulting in physical, psychological and social impairment (1), and health care costs (2,3). Within the last decade, research has demonstrated that 5-HT2A agonists including psilocybin and LSD elicit spiritual experiences (4) and functional connectivity changes between diverse brain areas (5). Therefore, it is pertinent to...